Rigel Pharmaceuticals Inc Sentiment Worsening on Bad Stock Potential, Now at 1.41

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Corporate Logo

“Big money” Positions

In Q3 2018 Rigel Pharmaceuticals Inc (NASDAQ:RIGL) big money sentiment decreased to 1.41, revealed SEC filings. That’s down -1.51, from 2018Q2’s 2.92. 58 hedge funds increased and started new stock positions, while 41 decreased and sold stakes in Rigel Pharmaceuticals Inc so the sentiment is negative. These funds own 142.07 million shares, that’s up from 141.97 million shares in 2018Q2. Funds holding Rigel Pharmaceuticals Inc in top 10 changed to 0 from 0 for the same number . In total 14 funds closed positions, 27 reduced and 36 increased. Also 22 funds bought new Rigel Pharmaceuticals Inc stakes.

Largest Rigel Pharmaceuticals Inc Shareholders

Sio Capital Management Llc owns 1.84 million shares in Rigel Pharmaceuticals Inc as of Q3 2018. Rigel Pharmaceuticals Inc’s shareholder Rhenman & Partners Asset Management Ab owns 2.11 million shares as of Q3 2018. Pura Vida Investments Llc reported 302,489 shares. Rock Springs Capital Management Lp revealed 4.13 million shares position in Rigel Pharmaceuticals Inc. The Maryland-based fund Nea Management Company Llc looks positive on Rigel Pharmaceuticals Inc, owning 3.24 million shares.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology.The company has $376.61 million market cap. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy.Currently it has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Ticker’s shares touched $2.26 during the last trading session after 0.44% change.Currently Rigel Pharmaceuticals, Inc. is downtrending after 29.12% change in last February 14, 2018. RIGL has 1.11 million shares volume. RIGL underperformed the S&P 500 by 29.12%.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)’s quarterly earnings will be revealed on March, 5., according to Faxor. This year’s earnings per share analyst estimate is expected to be $0.03. That is 116.67 % up compareed to $-0.18 earnings per share for last year. If earnings per share of $0.03 is revealed the profit of RIGL could reach $5.00 million giving it 18.83 P/E. Wall Street now forecasts -121.43 % EPS growth despite Rigel Pharmaceuticals, Inc. previous quarter’s EPS of $-0.14.

California Employees Retirement Sys invested in 508,094 shs or 0% of the stock. Dekabank Deutsche Girozentrale reported 62,500 shs. Axa holds 119,600 shs or 0% of its capital. 30,000 are owned by M Holdings Securities Incorporated. Daiwa Grp Incorporated has invested 0% of its capital in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Goldman Sachs Group holds 2.11M shs. Manufacturers Life Insur The reported 0% stake. National Bank Of America De invested in 42,024 shs or 0% of the stock. Dimensional Fund Advsrs Ltd Partnership reported 463,340 shs stake. Rhenman And Prns Asset Mgmt Ab accumulated 2.11 million shs or 0.68% of the stock. Schwab Charles Invest Management holds 0% or 367,231 shs. Credit Suisse Ag invested 0% of its capital in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Vanguard Group has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Hightower Advsrs accumulated 10,000 shs or 0% of the stock. California State Teachers Retirement has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Rigel Pharmaceuticals, Inc. had 4 insider sales and 2 buys since August 17, 2018. This’s net activity of $47,891. On Thursday, August 23 $282,320 worth of stock was bought by Mayer Eldon C. III. Shares for $300,002 were bought by RODRIGUEZ RAUL R. Another trade for 10,000 shs valued at $31,200 was made by Cabatuan Nelson on Friday, October 12.

For more Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news announced briefly go to: Prnewswire.com, Prnewswire.com, Nasdaq.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update – PR Newswire” announced on August 08, 2018, “Technological Advancements Show Growth in the Hospital Acquired Infection Control Market – PRNewswire” on November 16, 2018, “Synchrony Financial (SYF) Ex-Dividend Date Scheduled for August 03, 2018 – Nasdaq” with a publish date: August 02, 2018, “Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings – GlobeNewswire” and the last “Rigel Pharmaceuticals Is In Bargain Territory – Seeking Alpha” with publication date: April 25, 2018.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.